(Q37784388)

23 August 2017

title

Rechallenging with anthracyclines and taxanes in metastatic breast cancer (English)

1 reference

23 August 2017

main subject

metastatic breast cancer

1 reference

Carlo Palmieri

1

1 reference

23 August 2017

Jonathan Krell

2

1 reference

23 August 2017

Colin R James

3

1 reference

23 August 2017

Catherine Harper-Wynne

4

1 reference

23 August 2017

Vivek Misra

5

1 reference

23 August 2017

Susan Cleator

6

1 reference

23 August 2017

David Miles

7

1 reference

23 August 2017

language of work or name

English

0 references

publication date

31 August 2010

1 reference

Nature Reviews Clinical Oncology

23 August 2017

published in

1 reference

23 August 2017

volume

7

1 reference

23 August 2017

issue

10

1 reference

23 August 2017

page(s)

561-574

1 reference

Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Risk factors for doxorubicin-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Prolonged Disease-Free Survival in Hodgkin's Disease with MOPP Reinduction After First Relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Dihydroxyanthracenedione: A Promising New Drug in the Treatment of Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Treatment for anthracycline-pretreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast canc

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Small-Cell Carcinoma of Lung: Reinduction Therapy After Late Relapse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB Study 8081.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Reinduction with the same cytostatic treatment in patients with metastatic breast cancer: an Eastern Cooperative Oncology Group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

High-dose 4'-epiadriamycin for treatment of breast cancer refractory to standard dose anthracycline chemotherapy: achievement of second responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

FAC (fluorouracil, doxorubicin, cyclophosphamide) as second line chemotherapy in patients with metastatic breast cancer progressing under FEC (fluorouracil, epirubicin, cyclophosphamide) chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

A phase II trial of weekly high-dose folinic acid and 5-fluorouracil in combination with epirubicin as salvage chemotherapy in advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Randomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Adriamycin (doxorubicin), vinblastine, and mitomycin C combination chemotherapy in refractory breast carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

A comparison of mitoxantrone and doxorubicin in breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Response to second-line chemotherapy in patients with metastatic breast carcinoma previously responsive to first-line treatment: prognostic factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthra

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Phase II study of weekly paclitaxel for docetaxel-resistant metastatic breast cancer in Japan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.122

Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes

31 March 2020

1 reference

12 December 2020

First-line chemotherapy rechallenge after relapse in small cell lung cancer

1 reference

12 December 2020

Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study

1 reference

12 December 2020

Platinum containing regimens for metastatic breast cancer

1 reference

12 December 2020

A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer

1 reference

12 December 2020

10.1038/NRCLINONC.2010.122

Identifiers

DOI

1 reference

23 August 2017

1 reference